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DOI 10.1016/j.ccr.2012.01.008SUMMARYThe nature and site of tumor-antigen presentation to immune T cells by bone-marrow-derived cells within the
tumor microenvironment remains unresolved. We generated a fluorescent mouse model of spontaneous
immunoevasive breast cancer and identified a subset of myeloid cells with significant similarity to dendritic
cells and macrophages that constitutively ingest tumor-derived proteins and present processed tumor
antigens to reactive T cells. Using intravital live imaging, we determined that infiltrating tumor-specific
T cells engage in long-lived interactions with these cells, proximal to the tumor. In vitro, these cells capture
cytotoxic T cells in signaling-competent conjugates but do not support full activation or sustain cytolysis. The
spatiotemporal dynamics revealed here implicate nonproductive interactions between T cells and antigen-
presenting cells on the tumor margin.INTRODUCTION
Despite the recruitment of tumor-specific CD8+ tumor-infiltrating
lymphocytes (TILs) to the tumor microenvironment, the immune
response is limited in its ability to clear tumors (Drake et al.,
2006). Numerous lines of evidence suggest that tolerance to
tumors relies on presentation of peptide antigens on major
histocompatibility complex (MHC) molecules on the surface of
bone-marrow-derived antigen-presenting cells (APCs), as is
the case for other peripheral tissues (Adler et al., 1998; Heath
and Carbone, 2001; Kusmartsev et al., 2005; Sotomayor et al.,
2001). In recent years, broad classes of cell types derived from
the mononuclear phagocyte system (MPS), such as myeloid-
derived suppressor cells (MDSCs) and tumor-associatedmacro-
phages (TAMs), have been implicated in promoting tumor growth
and metastasis while inhibiting a productive immune response
by T cells (Gabrilovich and Nagaraj, 2009; Pollard, 2009). TAMs
increase metastasis in the PyMT breast cancer model (LinSignificance
The cells involved in presenting antigens to T cells at the tumo
tumors, we developed a fluorescent- and antigen-linked sponta
for ingesting tumor antigens and presenting them to T cells a
These cells fail to stimulate T cells and may serve as a barrie
the behavior of tolerized T cells within tumors and provides a
that the cells presenting antigens to T cells are a large subset
402 Cancer Cell 21, 402–417, March 20, 2012 ª2012 Elsevier Inc.et al., 2006), partly as a result of T cell skewing toward a Th2
phenotype (DeNardo et al., 2009). Isolated MDSCs bearing the
marker Gr-1, in contrast, inhibit T cell activation and suppress
the activation of T cells by secondary APCs or other stimuli
(Gabrilovich and Nagaraj, 2009; Terabe et al., 2003). There has,
however, been no direct identification of the cell type that phys-
ically mediates antigen uptake and presentation in the tumor
microenvironment.
Dendritic cells (DCs), another cell type derived from the MPS
that is very similar to macrophages, are the preeminent
APCs for T cells in lymphoid organs and in tissues. DCs in this
setting are clearly integral in activating T cells but may also
serve to tolerize them (Hawiger et al., 2001). The role of DCs in
tumors (TuDC) is less well understood, but their presence
is extensively documented. While the elicitation of a potent
T cell expansion by DCs is clearly an integral part of a successful
immunotherapy and can be augmented by transferring antigen-
pulsed DCs to hosts (Mayordomo et al., 1995), DCs in ther site are not defined. To better study the T cell response to
neousmodel of breast cancer. The primary cells responsible
re low-motility myeloid cells localized along tumor margins.
r to an effective T cell response. This model demonstrates
target for immunotherapies. Marker analysis demonstrates
of cells implicated in tumor remodeling.
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immune dysregulation. For example, the presence of specific
subsets of DCs, especially CD123+ plasmacytoid DCs (pDCs),
are associated with negative prognosis in human patients
(Ambe et al., 1989; Treilleux et al., 2004).
Delineating cell types of the MPS purely on surface phenotype
has proven difficult because TAMs, MDSCs, and DCs share
many common lineage markers. While direct staining of these
cells from sections provides information about the populations
in aggregate, it is likely that the MPS contributes a variety of
cell types to the microenvironment, all of which might be the
primary APCs for T cells. Real-time intravital imaging has shed
light on key processes during priming in the lymph node,
including the priming of T cells on DCs (Miller et al., 2002;
Mempel et al., 2004), and holds promise for delineating subsets
of APCs that are responsible for interacting with T cells. It has the
benefit of complementing phenotypic surface marker data with
morphological and behavioral phenotypes. Imaging of ectopic
thymomas (EL4s) using labeled T cell receptor (TCR) transgenic
cells has revealed long-lived antigen-dependent contacts as
well as effective killing between T cells and the tumor cells
during tumor rejection (Mrass et al., 2006). However, in those
models, there was no possibility to visualize or define the
APCs of the microenvironment or to study T cell interaction
with such bone-marrow-derived APCs. Furthermore, introduc-
tion of tumor-specific T cells in these models leads to tumor
regression, unlike the case in typical refractory tumors. Thus,
the interactions of T cells and APCs that accompany tumor toler-
ance have, as yet, remained largely unresolved.
To gain insights into the nature of tumor antigen presentation
and the nature of interactions between T cells and APCs in
refractory tumors, we have generated a spontaneous tumor
model of human breast cancer based on the well-described
MMTV-PyMT model (Guy et al., 1992) that incorporates tags
for both imaging and for T-cell characterization. This model
allows us to track uptake of a coexpressed protein-fluorophore
from tumor into the APC compartment. This study effectively
exposes a key cell type and its antigen uptake, presentation,
and activation capacities, as well as placing these activities
spatially within the tumor microenvironment.
RESULTS
Recruitment and Inactivity of Tumor-Specific T Cells
in a Spontaneous Model of Breast Cancer
To provide a method for tracking the flow of antigens from
tumor to T cell, we generated a spontaneous mouse model for
breast cancer in which the initiating oncogene and a neotumor
antigen are coexpressed with the stable fluorescent protein
mCherry, under a common breast epithelium-specific promoter.
For this, we adapted the extensively characterized mouse
mammary tumor virus-polyoma middle T (MMTV-PyMT) trans-
genic cassette (Guy et al., 1992), whose expression gives rise
to disease in mice that closely models many aspects of sponta-
neous luminal breast cancer, including characteristic stages
from hyperplasia to adenoma to carcinoma and ultimately to
metastatic disease (Lin et al., 2003). We introduced two self-
cleaving P2A sequences (de Felipe et al., 2003) downstream of
the PyMT cDNA to produce the mCherry and ovalbumin proteins(OVA) (Figure 1A). We included mCherry expression to aid in
visualization of transformed cells and to track antigen uptake in
the microenvironment. We included OVA to generate germline-
encoded self-antigens that were specific to cells expressing
the oncogene (‘‘tumor self’’) and could be recognized by well-
characterized CD8 T cells expressing the OT-I TCR. By coex-
pressing these genes in a common MMTV-driven transcript,
we ensured the coproduction of each protein, in concert with
onset of transformation, and yet allowed both mCherry and
OVA to be processed independently, thus preventing premature
degradation. The expression of these proteins as distinct
polypeptides was demonstrated by western blotting (Figure 1B),
where each individual protein is detected as a single band at the
expected molecular weight. The onset of tumors in this ‘‘PyMT
ChOVA’’ line was approximately 20 weeks of age on the
C57BL/6 background (Figure S1 available online). The >95%
penetrance of tumors and onset at times similar to those of the
parental PyMT strain on C57/BL6 background (data not shown)
suggested that the inclusion of the mCherry and OVA proteins
provided little benefit to the immune system’s ability to recognize
or control the tumor.
A sizeable fraction of the tumor antigens that have been
isolated from human tumors to date are nonmutated, germline-
encoded, tissue-specific proteins that are more dominantly
expressed by transformed cells (Finn et al., 1995; Kawakami
et al., 1994; van der Bruggen et al., 1991). In these cases, their
presumed expression in the thymus apparently leads to negative
selection of T cells bearing high-affinity TCRs, and data show
a prevalence of cytotoxic T cells (CTLs) with low avidity to these
tumor antigens (Gervois et al., 1996), with some notable excep-
tions identified using tetramers (Lee et al., 1999; Yee et al., 1999).
TheMMTV promoter used in the PyMT ChOVAmodel also drove
expression in the thymus, as indicated by the negative selection
of developing anti-OVA/antitumor OT-I TCR transgenic T cells
(Figure 1C). Thus, OVA in this mouse replicates partial central
tolerance to tumor antigens.
We next investigated the ability of high-affinity anti-OVA OT-I
T cells, introduced into mice already bearing tumors, to respond
in situ. Tumor-antigen presentation in PyMT ChOVA lymph
nodes was quite robust, as evidenced by proliferation-
dependent dilution of the vital dye CFSE specifically in naive
tumor-specific T cells (OT-I) in PyMT ChOVA mice, but not in
the PyMT mouse strain (Figure 1D). Similarly, introduced GFP-
labeled tumor-specific OT-I T cells were present in the tumor
and specifically proliferated and accumulated in the lymph
node, whereas nonspecific T cells did not expand or significantly
populate the tumor (Figure 1E). That the tumor antigen-specific
T cells expanded to over 10% of the CD45+ cells and then per-
sisted at high percentages at lymph nodes and tumor for over
30 days (Figure 1F) indicates that the primed cells were not
subject to strong deletional tolerance.
Tumor-Specific T Cells Are Incapable of Eliminating
PyMT ChOVA Tumors
Tumor-reactive naive T cells are efficiently activated in the
secondary lymphoid organs of PyMT ChOVA mice. However,
naive high-avidity T cells had only a slight effect in slowing tumor
growth and were unable to eliminate tumors when transferred to
tumor-bearing hosts (Figures 2A and 2B). These results areCancer Cell 21, 402–417, March 20, 2012 ª2012 Elsevier Inc. 403
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Figure 1. Recruitment and Ineffectiveness of Tumor-Specific T Cells in a Spontaneous Model of Breast Cancer
(A) Schematic of PyMT ChOVA transgenic construct.
(B) Western blots displaying the expression of PyMT, mCherry, and Ova from tumor cells and control T cells in PyMT ChOVA mice.
(C) Thymic negative selection of high-affinity TCRs in the PyMTChOVA spontaneous breast cancer model. Lymph nodes and thymii from wild-type B6, OT-I, or
PyMT ChOVA x OT-I mice were analyzed by flow cytometry for CD4 and CD8 expression.
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another spontaneous mouse model, TRAMP, in which lymph
node CTL activation fails to be sufficient to induce rejection
(Anderson et al., 2007). Notably, in our model, whereas tumor-
specific T cells primed for 5 days in the lymph node of tumor-
bearing mice demonstrated excellent cytolytic function against
antigen-bearing targets, CTL found in the tumor at that time
were effectively nonlytic (Figure 2C). That the latter were derived
from the former is suggested by the earlier kinetics of accumula-
tion and CFSE dilution in the lymph node relative to the tumor
(Figure 1F; data not shown). Overall, this result is similar to
human cancers such as melanoma in which tumor-antigen-
specific Melan-A/MART-1 tetramer staining demonstrates
expanded levels of tumor-specific cells in TILs relative to periph-
eral sites, coupled with the same profound failure to reject the
tumor (Lee et al., 1999; Romero et al., 1998).
We thus sought to determine the in vivo behavior of T cells in
our model. To this end, we turned to intravital imaging (Egeblad
et al., 2008), adoptively transferring naive GFP-labeled OT-I
T cells, allowing them to activate and traffic to tumors and subse-
quently imaging their interactions in the tumor. We observed
significant accumulations of T cells, often in multicellular clusters
and at distinct foci along the tumor borders (Figure 2D; Movie
S1). As motility appeared much slower near the tumor, we
defined a cutoff at 5 mm and considered cells within this radius
‘‘proximal,’’ whereas those further away are considered ‘‘distal.’’
In tumor-distal regions, T cells were largely motile, moving at
6 mm/min (Figure 2E), a speed only slightly slower than those
reported for unrestricted movements in lymph nodes (Miller
et al., 2002). However, in the proximal regions, where clusters
formed on the tumor margins, speeds were largely reduced to
an average of 3 mm/min, with many cells much slower. Radial
tracking plots of randomly selected cells supported the theory
that most of these cells were in fact swarming or jittering in the
proximal clustered regions (Figure 2F), whereas distally located
cells quickly diverged from the origin. We did not observe any
evidence for destruction of tumor cells by OVA-specific (OT-I)
T cells in these tumors, such as single-step loss of mCherry fluo-
rescence in cell-sized voxel regions, consistent with tumor
measurements that had previously shown that T cells had little
effect on tumor growth.
Phenotypic Characterization of Tumor Antigen
Cross-Presenting Dendritic Cells
In engineering the PyMT ChOVA model to coexpress mCherry,
we exploited this protein’s apparent resistance to degradation
to allow us to track antigens that are taken up from tumor cells
for presentation by neighboring cells. By flow cytometry, we
detected a population of mCherry+/CD45+ cells of hematopoi-
etic origin in single-cell suspensions of PyMT ChOVA but not
original PyMT tumors (Figure 3A). A majority of CD45+ cells posi-(D) Flow cytometry of tumor-draining lymph nodes 48 hr after 13 106 CFSE-label
or a PyMT ChOVA tumor-bearing mouse.
(E) A total of 53 106 OT-I-UbGFP T cells or polyclonal Ub-GFP CD8 T cells were t
draining lymph nodes and tumors were removed and analyzed by flow cytometr
(F) Tumor-bearing PyMT ChOVA mice received 1 3 106 CD45.1 OT-I cells intrav
lymph nodes and tumor were removed and analyzed by flow cytometry. Plots fro
See also Figure S1.tive for mCherry above background also expressed high levels of
CD11c, an integrin enriched in the dendritic cell lineage. To
demonstrate that the mCherry in these cells derived from inges-
tion of the protein, as opposed to production, we generated
bone marrow chimeras in which nontransgenic CD45.1+ bone
marrow introduced into PyMT ChOVA mice resulted in mCherry
fluorescence in CD11c+ cells of the adopted (transgene-nega-
tive) lineage (Figure 3B). We observed mCherry fluorescence
as puncta in isolated cells consistent with phagosomes (data
not shown) but were unable to detect significant levels of
mCherry transcripts in these cells (data not shown), consistent
with uptake.
Analysis of CD11c versus Gr-1 staining in the CD45+ mCher-
ryhi cells demonstrated that approximately 3/4 of the mCherryhi
cells expressed CD11c and less than 5% of them expressed
Gr-1, a marker closely associated with MDSC (Figure 3C). We
performed a similar analysis of CD11c and Gr-1 from the entire
CD45+ gate (Figure 3D) to characterize the infiltrate in aggregate
and thereby defined four populations: CD11c+Gr-1 (CD11c+),
CD11c Gr-1+ (Gr-1+), double-positive (CD11c+, Gr-1+), and
double-negative (DN). Staining for additional surface proteins
showed that none of these subsets expressed CD123, a marker
for pDCs; CD135, a marker for bone marrow progenitors; or
CD115, the CSF-1R. CD11c+ subsets coexpressed moderate
CD11b, whereasGr-1+ cells expressed distinctly high levels (Fig-
ure 3E). The CD11c+ populations also expressed high levels
of F4/80 and MHC II. The F4/80 expression together with
the CD11b positivity would also qualify this subset as a TAM
(Ojalvo et al., 2009). The CD11c+ population also had taken up
significantly more of the tumor-derived mCherry than the Gr-1+
or DN populations, although we note that this is bimodal,
suggesting the population is not homogeneous in this respect
(Figure 3E). The higher levels of both MHC II and mCherry
suggests that the CD11c+ cells are most likely to be effective
antigen-presenting cells for incoming effector T cells. We also
note that they are considerably more abundant within the tumor
relative to the other three populations. On an absolute scale,
the DP populations were most homogeneously mCherry
positive but represented less than 1% of the total isolate.
Less than 1% of CD11c+ cells expressed the pDC markers
CD123 (Figure 3E) and B220 (data not shown). The best correla-
tion with mCherry positivity was the marker F4/80 (data not
shown).
As we were interested in these cells as putative APCs, we next
compared the entire lineage of CD11c-positive cells from tumors
to splenic DCs and to in-vitro-matured, bone-marrow-derived
DCs (BMDCs). CD11c levels were just slightly lower on tumor
APCs as compared to BMDCs or splenic DCs (Figure 3F, left
panel). When CD11c+ TuDC cells were analyzed, we observed
roughly similar levels of MHCs and costimulatory molecule
expression in the tumor-associated cells and splenic DCs,ed CD45.1 OT-I T cells were transferred to either a PyMT tumor-bearing mouse
ransferred to PyMT ChOVA tumor-bearing mice. Five days posttransfer, tumor-
y. Plots from tumor were previously gated for CD45+ leukocytes.
enously and were sacrificed at the specified day posttransfer. Tumor-draining
m tumor were previously gated for CD45+ leukocytes.
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Figure 2. Tumor-Specific T Cells Are Defective in Their Ability to Eliminate PyMT ChOVA Tumors
(A) Tumor burden in individual PyMT ChOVA mice after adoptive transfer of 5 3 106 naive OT-I cells (red lines, n = 7) or untreated controls (black lines, n = 12).
Arrow indicates date of adoptive transfer.
(B) Average combined tumor burden in PyMTChOVAmice after adoptive transfer of 53 106 naiveOT-I cells (red line:mean (M) ± SEM, N= 7) or untreated controls
(black line: M ± SEM, N = 12).
(C) Cytotoxic activity of OT-I T cells isolated from the lymph nodes (LNs; green) or tumor (red) of PyMTChOva mice 5 days after adoptive transfer, compared to
in-vitro-activated control OT-I T cells (black line with triangles) or control OT-I lysis of unpulsed EL4s (black line with squares). A total of 104 EL-4 cells (±100 ng/ml
SL8 peptide pulse) were used as targets. All lines: M ± SEM, N = 3.
(D) Spinning disc confocal live imaging of OT-I GFP T cells 5 days after adoptive transfer into PyMT ChOVAmice. Representative image of T cell localization at the
site of a mCherry fluorescent tumor (left), image displaying tumor area outlined using a threshold mask (middle), and time-average image of T cell persistence at
the tumor site with tumors outlined (right). Scale bar, 50 mm.
(E) Average velocity of individual T cell tracks of cells located proximal (within 5 mm) or distal to the tumor.
(F) Representative displacement tracks from T cells located either proximal (within 5 mm) or distal to the tumor border.
See also Movie S1.
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Imaging the Path from Tumor Antigens to Tolerancesuggesting that they would be similarly capable of presenting
antigen to naive T cells (Figure 3F). Although many CD11c+ cells
at the tumor site were mCherry+, there was still significant
heterogeneity within the CD11c+ population for the amount of
mCherry that had been ingested. This could reflect that not all
cells are in a position to effectively take up the antigen or that
the cells degrade the protein over time.406 Cancer Cell 21, 402–417, March 20, 2012 ª2012 Elsevier Inc.Live Imaging of Tumor Dendritic Cell Behavior
Given the presence of the CD11c protein on the majority of the
mCherryhi cells of interest, we interbred PyMT ChOVA mice
with mice that express yellow fluorescent protein (YFP) under
the control of the CD11c promoter (Lindquist et al., 2004),
permitting us to visualize the location and behavior of these
APCs directly through real-time intravital live imaging of exposed
Cancer Cell
Imaging the Path from Tumor Antigens to Tolerancetumor masses. Using the same 5 mm proximity cutoffs as in Fig-
ure 2, we characterized tumor-proximal CD11c+ cells that were
closely juxtaposed with the tumor and had very low motility
compared to distal cells (Figures 4A–4C and 4H; Movies S2
and S3). The proximal CD11c-YFP+ cells of the tumors also
had the highest level of mCherry fluorescence (Figures 4D, 4E,
and 4G;Movie S3). The observation of the behavior of these cells
in vivo supported our previous observation that CD11c+ cells in-
gested tumor antigens and eliminated the possibility that the
mCherry fluorescence that we observe by flow cytometry is
simply an artifact of in vitro digestion of the tumor. Flow cytom-
etry of tumor from PyMTChOVA x CD11c YFPmice also demon-
strated that CD11c-YFP+ cells from the tumor had taken up
mCherry to an extent similar to that in cells stained with anti-
bodies against CD11c supporting the finding that the transgene
is generally faithful to the native protein (Figure 4F). Proximal
CD11c-YFP+ cells contained significant amounts of mCherry
signal in their cytoplasm, often in puncta suggestive of endocytic
vesicles, while distal CD11c-YFP+ cells did not contain these
structures(Figure 4G). Despite not moving their cell bodies along
the tumor margin, these proximal cells dynamically extended
and retracted dendrites, which is suggestive of ongoing
sampling of the environment (Figure 4H; Movie S3). Morpholog-
ical data complement phenotypic markers in supporting an
assignment of CD11c+ cells from the tumor as DCs, although it
is important to remember that the lineages are highly plastic as
previously discussed, and these cells may equally be called
TAMs on the basis of flow cytometry.
Changes in Myeloid Cell Populations during Tumor
Development
Having identified CD11c+ cells as important in ingesting tumor
antigens, we sought to characterize whether they were a consis-
tent feature of the tumor acrossmultiple stages. An advantage of
the PyMT model is that tumors of distinct developmental stages
exist in the same mouse. We identified mice with large carci-
nomas (area > 100 mm2) and adenomas (barely palpable
tumors < 9 mm2) at different mammary glands (Figure 5A) and
dissociated these tumors for analysis by flow cytometry. After
gating on the CD45+ leukocytic infiltrate, we again analyzed
the levels of the common myeloid markers, Gr-1, CD11c,
CD11b, and F4/80 (Figure 5B). We found that the numbers of
cells positive for Gr-1 were significantly higher in carcinomas
than adenomas, while CD11c and F4/80 were only modestly
increased (Figure 5C). Together, these data suggest that the
CD11c+ population is a consistent component of tumors across
multiple stages and not restricted to early or late tumors.
Tumor DCs Interact with Tumor-Specific T Cells In Vitro
and In Vivo
Armed with the knowledge that this population of CD11c+ cells
ingest tumor antigens specifically along the tumor margin, we
noted that this locationwould also ideally place them in a position
to interact with the swarming/arrested antigen-specific T cells
that we had visualized earlier. To test whether this was the
case, we modified our cell-labeling approach to allow direct
assessment of interactions between T cells and CD11c+. For
this, we transferred OT-I cells derived from mice interbred with
the CD2RFP strain, which expresses the RFP protein at a veryhigh level in T cells. We thereby could coimage reactive T cells
and the proximal CD11c+ DC in a PyMT ChOVA x CD11c-YFP
mouse. In this setting, the mCherry expression of the tumor
was considerably less than the RFP-expressing T cells, allowing
the latter to be viewed distinctly. We observed both clusters and
individual T cells interacting for prolonged periods with tumor-
marginal DCs (Figure 6A; Movie S4). We also observed interac-
tions of multiple T cells and DCs that were stable (white arrows)
and conjugates of a single T cell with a single DC that formed
(blue arrow) or dissipated (yellow arrow) over time.
Analysis of larger fields, using color coding that differentiates
lone T cells and DCs from those that are interacting, visually
demonstrated that interactions between T cells and DCs were
less frequent and more transient in the distal region of the tumor
as compared to the proximal region (Figure 6B;Movie S5). Quan-
tification of T cell behaviors overmultiple sites demonstrated that
the majority of those in clusters, as observed in Figure 6A, were
attached to a tumor-proximal DC. Additionally, when individual
contacts between T cells and DCs were scored, a large fraction
persisted in contact with one another for more than 5 min, with
some persisting beyond the 30 min of our standard imaging
session. Many of the T cells in the dense clusters persisted there
for at least the 30 min periods of our observation. Additionally,
when we analyzed whether individual T cells had interacted
with a DC during the course of our 30 min imaging session, we
found that, by 30 min, 96% (147/153) of T cells had interacted
with DCs (defined as contacting DCs), while at the start of acqui-
sition, 56% (85/153) were in contact with DCs. This evidence
supports the theory that tumor-proximal T cells are preferentially
localized together with the mCherryhi CD11c+ cells in this local
environment and that they are effectively engaged in both pro-
longed and ongoing interactions.
We thus sought to test specifically whether these APCs were
more likely to form stable interactions with tumor-specific
T cells compared to the OVA+ tumor cells themselves. As it
was not possible to distinguish all cell types simultaneously
during intravital imaging, we turned to an in vitro system to study
T cell coupling frequencies with specific cells of the tumormicro-
environment. We prepared single-cell suspensions of all cells
from a PyMT ChOVA tumor and allowed the collections of tumor
and stromal cells to form couples with a significant excess of
in-vitro-activated OT-I T cells and then stained for surface
markers to delineate the tumor-derived populations that had
interacted. Using CD45+ and MHC II+ as a strategy to highlight
all potential APCs with tumor, we demonstrated that T cells pref-
erentially coupled with bone-marrow-derived APCs by this defi-
nition compared to tumor cells, even though the latter vastly
outnumber them (Figures 6C and 6D). Strikingly, T-cell-engaged
APCs had higher levels of mCherry fluorescence than those that
failed to couple, suggesting that the T cells differentially couple
to the mCherryhi cells (Figure 6E), corresponding to the high
frequency of T cell arrest on thoseproximalmCherryhi cells in vivo
(Figure 6B). We applied the same technique to determine if
CD11c+ or GR-1+ cells were more likely to interact with OT-I
T cells and found that CD11c+ cells were significantly better at
forming couples with T cells (Figures 6F and 6G). These results
corroborate the observations made during intravital imaging
and confirm that T cells preferentially interact with CD11c+ cells
when given the opportunity to choose their partner.Cancer Cell 21, 402–417, March 20, 2012 ª2012 Elsevier Inc. 407
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Figure 3. Phenotypic Characterization of Tumor-Antigen Cross-Presenting DCs
(A) Flow cytometry of CD45 expression versus mCherry levels from digested tumor from PyMT (left) or PyMT ChOVA (middle) mice. CD11c levels of gated CD45+
mCherry+ cells (right) from a previous dot plot.
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to bind pMHC since overall downregulation of the complex is
associated with recent signaling (Valitutti et al., 1995) but
absence of pMHC binding with presence of the a/b complex
has been previously associated with tumor tolerance (Nagaraj
et al., 2007). We thus tested the ability of both lymph-node-
and tumor-infiltrating T cells to bind to OVA-labeled Kb pentam-
ers 5 days after adoptive transfer into tumor-bearing hosts. We
found that both lymph node and tumor OT-I cells both showed
decreased levels of pentamer binding in comparison to OT-I
cells that were stimulated and then rested for 6 days in vitro,
with tumor OT-I showing the lowest level of staining (Figure S2).
We similarly determined by staining for the Vb5 of the OTI TCR
that this was decreased in a similar hierarchy in these cells
compared to blasted/rested OT-I (Figure S2). We interpret these
data as being consistent with ongoing TCR engagement at both
lymph node and tumor, leading to downregulation of the entire
TCR complex, but not a specific alteration of TCR binding capa-
bilities (e.g., Nagaraj et al., 2007).
Tumor DCs Activate Naive but Not Previously Activated
OT-I T Cells
Since activated T cells preferentially interact with theCD11c+ cell
populations both in vitro and in vivo, we sought to define the
ability of these CD11c+ cells to interact with and stimulate
T cells in vitro. Given their cell surface similarity to splenic DC
and their mCherry positive phenotype, we were not surprised
to find that a total CD11c+/MHC II+ population, freshly isolated
from tumors and without added antigen (TuDCs), stimulated
the proliferation of naive OVA-specific (OT-I) T cells in vitro (Fig-
ure 7A) at lower but still significantly above background levels
compared to BMDCs that had been pulsed with exogenous
peptides. This finding established that the TuDCs process and
display antigens in peptide-MHC complexes and are capable
of stimulating naive T cells, a feature sometimes associated
with mature myeloid populations such as mature DCs. However,
when assayed for the ability to support proliferation of estab-
lished CTLs, the tumor-derived antigen-bearing DCs proved
unexpectedly incapable of driving cell division. This deficit was
true across a wide range of concentrations of DCs and even
when exogenous peptides were added to the TuDCs (Figure 7B),
suggesting that the block was profound.
However, live imaging of CTLs, labeled with the calcium dye
FURA-2 and interactingwith TuDCs, demonstrated that proximal
activation occurred in CTL and that peptide-MHC triggering of
TCRs at the site of these interactions was not defective (Fig-
ure 7C; Movies S6 and S7). Both the percentage of cells that
generated calcium transients during interaction (Figure 7D) and
the magnitude of calcium curves generated by a panel of cells
(Figure 7E) were similar between TuDCs and the stimulatory(B) Flow cytometry of CD45.1 expression versus mCherry levels from bone marr
PyMT ChOVA mouse.
(C) CD45 expression versus mCherry levels from digested tumor from PyMT ChO
plot and analyzed for their expression of CD11c and Gr-1.
(D) CD45 expression versus mCherry levels from digested tumor from PyMT Ch
analyzed for their expression of CD11c and Gr-1.
(E) Gated and labeled populations from (3D) were analyzed for their expression o
(F) CD11c+ cells from the spleens of B6 mice, BMDC cultures, or the tumor of PyMBMDC population pulsed with exogenous peptides. These
results are consistent with peptide-MHC expression on these
cells but suggest that TuDCs apparently might bear inhibitory
ligands that function distal to synapse formation and TCR
signaling and inhibit productive responses. We also tested the
ability of TuDCs to induce upregulation of CD69 on previously
activated T cells and found that CD69 is upregulated by T cells
stimulated by both BMDCs pulsed with peptide and TuDCs (Fig-
ure S3). These data support the conclusion that TuDCs are
indeed antigen positive and are also able to initiate early events
of TCR signaling. We screened a large number of candidate
molecules and pathways and eliminated the canonical T cell
inhibitory pathways that are suggested to function in MDSCs,
M2 macrophages, and other APCs, including both surface
receptors and soluble factors (Figure S3). That none of these
restored proliferation suggests an unknown mechanism of
T cell inhibition.
Given the ability of these TuDCs to support antigen-depen-
dent coupling with CTLs in vitro and in vivo, we sought to deter-
mine the downstream effects of these signaling interactions. We
therefore tested the ability of CTLs encountering the TuDCs to
maintain CTL function, a key deficit in T cells that had homed
to the tumor (Figure 2). Comparisons of cytolysis by T cells
cultured with TuDCs showed that this interaction does not
sustain cytolytic function, similar to T cells cultured alone or
T cells stimulated with BMDCs without peptide. In contrast,
T cells cultured with BMDC pulsed with peptides or T cells
cultured alone or with TuDCs in the presence of interleukin-2
(IL-2) did maintain cytolytic acitivity (Figure 7F).
As we were unable to restore proliferation effectively by block-
ing established inhibitory pathways in these assays, we also
sought to reverse the phenotype bymodulating theDC.Maturing
the TuDCs by adding either imiquimod or CpG to the stimulation
reaction strikingly relicensed them to stimulate CTLs to further
divide (Figure 7G). These two agents are agonists for APC-ex-
pressed toll-like receptors (TLRs) 7 and 9, respectively, and
neither agent had significant effects on the T cells (data not
shown). As a control, cells were treated without effect by
applying lipopolysaccharide (LPS), an agonist to TLR4, which
is poorly expressed by TuDCs (data not shown). Supplementing
the stimulation reaction with exogenous cytokines, whether IL-2,
IL-12, or IL-15, also was able to rescue the proliferative defect
(Figure 7H). Together, our data suggest a specific stimulatory
defect of TuDCs in their interactions with CTL, separate from
antigen processing and presentation.
Given the ability of these TuDCs to support antigen-depen-
dent interactions with CTLs, we finally sought to determine
whether TuDCs suppress CTLs from responding to other
antigen-presenting cells. While, in some experiments, inhibition
was profound, it was inconsistent over 13 experiments with anow chimera made by adoption of CD45.1 bone marrow cells into an irradiated
VA mouse, gated CD45+ mCherryhi cells were propagated to subsequent dot
OVA mouse, gated CD45+ cells were propagated to subsequent dot plot and
f the listed cell surface markers or for their mCherry fluorescence level.
T ChOVA mice. Gate in left histogram propagated to subsequent histograms.
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Figure 4. Live Imaging of Tumor-DC Behavior
(A) Representative still image acquired by intravital spinning disc confocal microscopy of mCherry+ CD11c YFP+ DCs in PyMT ChOVA x CD11c YFP mice.
Scale bar, 10 mm.
(B) DCs are color coded based on their proximity to the tumor border. Proximal DCs (within 5 mm) are coded yellow, and distal DCs (>5 mm from tumor border) are
coded blue. Color-coded DCs with representative tracks of their movement during imaging.
(C) Average velocity of individual CD11c YFP+ cells located proximal or distal to the tumor border.
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Figure 5. Alteration of Leukocytic Infiltrate with Tumor Development
(A) Transmitted and mCherry-fluorescent images of tumors from PyMT ChOVA mouse taken on a dissecting scope. Scale bar, 1 cm.
(B) Cells from either an adenoma or a late carcinoma tumor were dissociated and analyzed by flow cytometry. CD45+ cells were analyzed for the cell surface
markers CD11c, Gr-1, CD11b, and F4/80.
(C) Plots depict percent positive for specified cell surface markers out total CD45+ cells from tumors at different stages. Each data point represents one tumor,
and matched colors indicate tumors were from the same mouse.
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Imaging the Path from Tumor Antigens to Toleranceaverage of just 30% inhibition (Figure S3). Since we do not yet
understand themechanisms utilized, any dominant suppression,
if present, may also be sensitive to culture conditions or may be
reversible (e.g., see Figure 7G). Alternatively, given the paucity of
other effective APCs in the tumor microenvironment, tolerance
may result purely from ineffective or defective repriming.
DISCUSSION
Delineating APCs in Tumors
Using a spontaneous mouse model of breast cancer, we have
identified a population of myeloid cells that is optimized for
ingesting and presenting tumor antigens to CD8 T cells and,(D) Representative still image acquired by intravital spinning disc confocal micro
(E) Mean fluorescent intensity of CD11c YFP+ cells located proximal or distal to th
background fluorescence of image.
(F) Flow cytometry analysis of CD11c-YFP x PyMT ChOVA mouse displaying CD
(G) Representative YFP, mCherry, and overlay still images of DCs either proxima
(H) Representative still images of YFP+ cells displaying either dendritic-like or mo
See also Movies S2 and S3.thus, is a clear and relevant APC of the tumor microenvironment.
This formal identification is an important finding since many cells
are likely capable of antigen presentation in vitro when pulsed
appropriately with peptides, yet no previous study has been
able to unequivocally define the cells that interact with tumor-
specific T cells within tumors. The direct demonstration of their
presence at the site of T cell arrest along the margin suggest
that they fill this roll in vivo as well as in vitro.
Ojalvo et al. recently described TAMs as c-fmsGFP+ F4/80+
and dextran+ (Ojalvo et al., 2009); by this definition, themCherry+
cells that we describe here could also be classified as TAMs, as
they are CD11b+ and F4/80+ and their mCherry positivity largely
substitutes for dextran+ as a marker of phagocytic ability (J.J.E.scopy of mCherry+ CD11c YFP+ DCs in PyMT ChOVA x CD11c YFP mice.
e tumor border, and tumor masses. Line indicated with an asterisk represents
11c YFP+ mCherry+ DCs.
l or distal to the tumor. Scale bar, 10 mm.
tile cell behaviors. Cell outlines are marked in dashed lines. Scale bar, 10 mm.
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Figure 6. Tumor DCs Interact with Tumor-Specific T Cells In Vitro and In Vivo
(A) Spinning disc confocal imaging of CD2RFPOT-I T cells 5 days after adoptive transfer to PyMTChOVA xCD11c-YFPmice. A representative image sequence of
CD2RFP T cells (red) interacting with CD11c-YFP (green) DCs at the tumor site; white arrows indicate T cells interacting with DCs throughout the time lapse,
yellow arrows indicate a T cell leaving an interaction with a DC, and blue arrows indicate a T cell moving to a DC. Scale bar, 30 mm.
(B) Representative image displaying T cells (red) and DCs (green) at the tumor site. Blue cells indicate DCs contacting T cells (defined by overlapping red and
green fluorescence), and white cells indicate T cells contacting DCs. Scale bar, 50 mm. Inset/top: Graph of the number of T cell clusters (defined as stable groups
of greater than 2 T cells) that occur with DCs present or without DCs present. Inset/bottom: Relative frequency of contact duration between OT-I T cells and
TuDCs. Pairs with contact durations lower than 200 s were not considered.
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Imaging the Path from Tumor Antigens to Toleranceand M.F.K., unpublished data). Although we do not find signifi-
cant expression of CD115, the protein product of the c-fms
GFP reporter, the TuDC population we describe otherwise can
be considered a substantial subset of TAMs as well, and the
nomenclature discrepancy in the literature may ultimately
resolve these on the basis of data such as ours. The plasticity
and overlap of cell surface markers makes the study and classi-
fication of these cells difficult, but we suggest classifying these
cells as dendritic cells for immunological purposes, based on
their cell surface marker expression and in vivo morphology
and behavior. This apparent equivalency in the literature is
then intriguing, as some of the same cells that are implicated in
tolerizing T cells are also those implicated in remodeling and
angiogenesis (Schoppmann et al., 2002; Qian and Pollard, 2010).
We have excluded tumor APCs from the MDSC population
because of their lack of expression of the defining marker for
this population, Gr-1, and furthermore because the CD11c+ cells
do not function in analogous manner; namely, defective prolifer-
ation is not restored with iNOS and/or Arginase inhibition (Fig-
ure S2) (Gabrilovich and Nagaraj, 2009). Although we identify
CD11c+ cells to be a distinct subset of cells from the entire
lineage of the MPS, we acknowledge that some of these cells
have previously been described by others as TAMs (DeNardo
et al., 2009) or MDSCs or that some of our cells may share
phenotypic or functional characteristics of these populations.
However, the method that we have used clearly highlights this
population of cells on the basis of location, morphology, phago-
cytosis, and their unique interactions with infiltrating T cells. It is
also important to note that transient TCR-triggering interactions
might occurwith other APCs at sites besides the proximal region,
and we cannot rule out interactions between T cells and the few
CD11c mCherry+ APCs. We have demonstrated in the lymph
nodes that even transient interactions can trigger TCR clustering
and/or internalization (Friedman et al., 2010). Although, with our
in vitro coupling experiments and in vivo behavioral studies, we
established that CD11c+ TuDC are the predominant partners
for T cells, this by no means excludes other members of the
MPS from ever acting on T cells via antigen receptors.
Despite the robust mCherry signal in tumor CD45+ cells, we
were unable to detect mCherry+ DCs in the tumor-draining
lymph nodes (data not shown). It thus remains unknown how
and by which cells antigen is being presented to lymph node
T cells. DCs from the tumor site may be trafficking to lymph
nodes but degrading the mCherry protein, or soluble tumor anti-
gens may travel through the lymph directly.
The Behavior of Tumor-Specific T Cells in Refractory
Tumors
In addition to identifying the tumor antigen cross-presenting DCs
at the tumor site, we were also able to study the behavior of
tumor antigen-specific T cells in a spontaneous and progressive
model that is refractory to large numbers of infiltrating tumor-(C) Histogram displaying the percentage of tumor cells (left) or MHC II+ cells (righ
(D) Results from six separate coupling assays plotted as percentage of tumor or
(E) mCherry fluorescence of CD45+ MHC class II+ cells that were not coupled to
(F) Histogram displaying the percentage of mCherry+ CD11c+ or CD45+ Gr-1+ ce
(G) Results from four separate coupling assays plotted as percentage of CD11c
See also Figure S2 and Movies S4 and S5.specific T cells. While activation and proliferation of naive
tumor-specific T cells was robust in the lymph node, these
T cells were shown to be defective at lysis of targets after expo-
sure to the tumor microenvironment. This lack of cytolytic ability
correlated with a lack of therapeutic benefit to adoptive transfer
of T cells. This inactivity is similar to what is seen in human vacci-
nation trials where large numbers of tumor-specific T cells can
be elicited without eliminating tumors (Gattinoni et al., 2006;
Rosenberg et al., 2005), suggesting a later defect, as we are
observing in this model. The ability of exogenous gc cytokines
to restore proliferation of T cells is also consistent with higher
levels of efficacy of adoptive cell therapy when combined with
IL-2 or IL-15 administration (Gattinoni et al., 2005; Overwijk
et al., 2003; Epardaud et al., 2008).
Intravital imaging in our model revealed strong long-lasting
interactions between tumor-specific T cells andDCs at the tumor
site. The importance of interactions between T cells and DCs at
the effector site of an immune response is an emerging field of
study; in the case of viral infections, the stimulation of memory
or effector cells by DCs at peripheral sites is thought to be impor-
tant for effective viral immunity (Wakim et al., 2008). The behavior
of these ineffective tumor-specific T cells is different from the
behavior of tumor-rejecting T cells described in previous studies
of ectopic tumor models (Mrass et al., 2006). While that study
highlighted the activity of a strongly productive T cell response
to a tumor, our study represents the activity occurring in a tumor
setting that is more representative of naturally occurring human
disease, where TILs are not effective in controlling tumor growth.
It remains to be determined why T cells preferentially interact
with TuDCs as compared to other cells of the tumor, and it is
intriguing to conjecture that a specific chemokine-driven interac-
tion may also contribute both to cell positioning within the tumor
and, perhaps, to the limited stimulation capacity.
Tolerance Induction through T-APC Interactions
within the Tumor
The concept that a BMDC serves to tolerize T cells that interact
with them as cognate APCs is not unprecedented. Tolerance in
the lymph node occurs when antigens are directed to
DEC205+ DCs in the lymph nodes in the absence of additional
stimuli (Hawiger et al., 2001). Adler et al. broadly described the
requirement for MHC-matched BMDCs in the tolerance to
a tissue-restricted antigen (Adler et al., 1998), and induction of
tolerance to an A20 lymphoma required matched bone marrow
cells and not the tumors themselves (Sotomayor et al., 2001).
Based on our in vitro studies, we propose that the interaction
between T cells and DCs may in fact inhibit the ongoing T cell
response or, alternatively, may simply fail to effectively restimu-
late T cells to control the tumor while diverting them into such
‘‘sterile’’ interactions. After isolation of tumor DCs, we found
that they were capable of activating naive T cells to proliferate
but not in-vitro-generated activated T cells. A recent reportt) from PyMT ChOVA tumors that form couples with DDAO-labeled T cells.
MHC II+ cells coupled to T cells. Bar represents mean.
T cells (shaded histogram) or were coupled to T cells (red histogram).
lls that form couples with OT-I GFP T cells.
or GR-1+ cells coupled to T cells. Bar represents mean.
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carcinoma demonstrated an inhibitory phenotype for these cells
when exogenously pulsed with peptides and used to stimulate
naive CD8 T cells (Norian et al., 2009). While similar to our find-
ings, the differences—that our cells are able to stimulate naive
CD8s while theirs are not and that their inhibition was mediated
by arginine metabolism—suggest that the mechanism of inhibi-
tion is distinct.
The defect in T cell restimulation exhibited by TuDCs could be
rescued by treatment of the cultures with the TLR agonists CpG
DNA and imiquimod. These data suggest that TuDCs are either
specifically lacking a stimulatory signal or are actively giving an
inhibitory signal that is distinct from other stimulatory DCs. These
data are consistent with a previous study in another sponta-
neous tumor model, RIP-Tag, where adoptive cell therapy was
only effective in conjunction with CpG administration (Garbi
et al., 2004) Similarly, topical administration of imiquimod was
effective against some established tumors in an ectopic model
(Lu et al., 2010), and it is tempting to speculate that this TuDC/
CTL axis is being modulated in that case. Topical application
of imiquimod to breast tissue was not effective in our hands
(data not shown). TuDCs from imiquimod-treated mice or after
treatment in vitro had similar levels of MHC II, CD80, and CD86
when compared to untreated TuDCs. Our highest doses of
imiquimod sometimes led to tumor hemorrhaging, and so we
suspect that a more direct approach toward modifying TuDC
function will be necessary.
Additional in vitro data correlate the functionally inactive T cells
at the tumor site to DC interactions. T cells cultured with tumor
DCs, but not stimulatory BMDCs, are unable to maintain lytic
activity against targets, again suggesting that this interaction is
deficient in its ability to promote a strong tumor response.
Both the intravital imaging detailing interactions between
T cells and DCs at the tumor site and in vitro coupling assays
indicate that T cells are preferentially drawn to DCs as they enter
the tumor microenvironment. Since this interaction fails to
promote T cell effector function, it may be a significant impedi-
ment to the ongoing tumor response.
Does this represent a new mechanism of T cell tolerance? We
have examined a large variety of surface receptor and soluble
mediators and find that these do not revert inhibition and allow
proliferation. It is interesting that we can demonstrate that prox-
imal signaling, both as assessed by calcium signaling and, indi-Figure 7. Tumor DCs Activate Naive but Not Previously Activated OT-I
(A) Proliferation of either naive (upper) or previously activated (lower) OT-I T cel
100 ng/ml SL8 peptide. N = 3 M ± SEM.
(B) Proliferation of previously activated OT-I T cells cultured with varying numb
N = 3 M ± SEM.
(C) Live imaging of previously activated and Fura-2 labeled OT-I T cells interacti
images are overlaid with a pseudocolor image of the ratiometric Fura-2 fluoresc
intracellular calcium represented in red. Scale bar, 10 mm.
(D) Frequency of cell contacts with SL8 peptide-pulsed BMDCs or TuDCs that le
(E) Intracellular calcium levels of previously activated OT-I T cells contacting BM
errors are shown.
(F). Cytolytic activity of in-vitro-activated T cells after overnight culture with BMD
(G) Proliferation of OT-I T cells cultured with TuDCs alone or TuDCswith the TLR li
(H) Proliferation of OT-I T cells cultured with either control splenocytes pulsed with
(10 ng/ml), or IL-15(10 ng/ml). N = 3 M ± SEM.
See also Figure S3 and Movies S6 and S7.rectly, through the formation of stable T cell and TuDC couples,
is intact. Otten and Germain had previously described a state of
‘‘split anergy’’ in CTL clones; T cells retained cytotoxicity but lost
proliferation and IL-2 secretion, when these lines engaged
partially fixed APCs (Otten and Germain, 1991). The situation in
response to TuDCs has interesting parallels, although inverted;
the key defect for tumor rejection may in fact be the loss of
CTL function.
Implications for Immunotherapy
Current immunotherapies focus on promoting a strong antitumor
T cell response by altering the T cells themselves, either by
increasing tumor-specific T cell frequency by adoptive cell trans-
fer (Dudley et al., 2002), increasing the reactivity of responding
T cells by engineering of high-avidity TCRs specific for tumors
(Park et al., 2011), or by eliciting more potent T cells by blockade
of inhibitory costimulatory molecules such as CTLA-4 or PD-1.
While CTLA-4 blockade, in particular, has shown promise in
treating human melanoma, many patients still show no clinical
response after treatment (Hodi et al., 2010). The reasons behind
this are unknown, but our data suggest that tumor-based APCs
may function by a unique mechanism and that combination
therapy to boost T cell responses via CTLA-4 blockade in
conjunction with treatments that alter TuDC stimulatory capacity
may be particularly effective. Our model in many ways repre-
sents a best-case scenario for immunotherapy in that we have
available a large number of high-avidity, tumor-specific T cells
for adoptive therapy. That treatment with this therapy still fails
highlights the need to search for other ways to enhance the
T cell response within tumors.
EXPERIMENTAL PROCEDURES
Mice and Genotyping
PyMT ChOVA transgenic C57BL/6 founder mice were generated as described
in the associated Supplemental Information. All other mice are as described in
the Supplemental Information. All mice weremaintained inmicroisolator cages
and treated in accordance with National Institutes of Health (NIH) and Amer-
ican Association of Laboratory Animal Care standards, consistent with the
animal care and use regulations of the Institutional Animal Care and Use
Committee of the University of California, San Francisco (UCSF).
Cell Tracking and Imaging Analysis
We visualized and analyzed data using Imaris 5.7.2 and 7.0 Software
(Bitplane). Individual cells were identified and tracked by Imaris, and cell speedT Cells
ls activated with either sorted TuDCs (50,000) or BMDCs (5,000) pulsed with
ers of TuDCs or BMDCs pulsed with the specified amount of SL8 peptide.
ng with BMDCs pulsed with 100 ng/ml SL8 peptide or with TuDCs. Brightfield
ence values, with low intracellular calcium levels represented in blue and high
ad to calcium transients in previously activated OT-I T cells. N = 3 M ± SEM.
DCs pulsed with 100 ng/ml SL8 peptide or TuDC. Mean values with standard
Cs, TuDCs, or BMDCs pulsed with 100 ng/ml SL8 peptide. N = 3 M ± SEM.
gands, LPS (1 mg/ml), imiquimod (2.5 mg/ml), or CpG (10 mg/ml). N = 3M ± SEM.
100 ng/ml SL8 peptide or TuDCs alone or in the presence of IL-2 (3 U/ml), IL-12
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Imaging the Path from Tumor Antigens to Toleranceand displacement were calculated from tracks. Mean fluorescence intensity of
mCherry in CD11c YFP DCswas calculated using iso-surfaces of masked DCs
from MATLAB segmentation. Contact duration was determined by calculated
track duration of masked T cell and DC couples that were tracked using Imaris.
T cell clusters for analysis of presence of DCs in couples were defined as
clusters of T cells containing more than two T cells. The presence of DCs
contacting these clusters was determined by visual inspection. Statistical
analysis of speeds, stopping times, mean fluorescence intensity, and interac-
tion times was conducted with Prism 4.0 (GraphPad Software), using an
unpaired t test and a two-tailed 95% confidence interval.
Statistical Analysis
Statistical analyses were performed with GraphPad Prism. Unless specifically
noted, all data are representative of >3 separate experiments. Error bars repre-
sent SEM, were calculated using Prism, and are derived from triplicate exper-
imental conditions. Specific statistical tests used were paired and unpaired
t tests, and all p values < 0.05 were considered statistically significant.SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures, Supplemental Experimental
Procedures, and seven movies and can be found with this article online at
doi:10.1016/j.ccr.2012.01.008.
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